SNDX

Company Overview — What Does Syndax Pharmaceuticals Inc Do?

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts. Syndax Pharmaceuticals Inc (SNDX) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael A. Metzger and employs approximately 110 people, headquartered in WALTHAM, Massachusetts. With a market capitalization of $2.1B, SNDX is one of the notable companies in the Healthcare sector.

Syndax Pharmaceuticals Inc (SNDX) Stock Rating — Hold (April 2026)

As of April 2026, Syndax Pharmaceuticals Inc receives a Hold rating with a composite score of 30.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.SNDX ranks #1,649 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Syndax Pharmaceuticals Inc ranks #150 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SNDX Stock Price and 52-Week Range

Syndax Pharmaceuticals Inc (SNDX) currently trades at $24.76. The 52-week high for SNDX is $25.16, which means the stock is currently trading -1.6% from its annual peak. The 52-week low is $8.58, putting the stock 188.6% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is SNDX Overvalued or Undervalued? — Valuation Analysis

Syndax Pharmaceuticals Inc (SNDX) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 33.63x, versus the sector average of 2.75x. The price-to-sales ratio is 18.68x, compared to 1.66x for the average Healthcare stock.

At current multiples, Syndax Pharmaceuticals Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Syndax Pharmaceuticals Inc Profitability — ROE, Margins, and Quality Score

Syndax Pharmaceuticals Inc (SNDX) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -466.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -56.9% versus the sector average of -33.1%.

On a margin basis, Syndax Pharmaceuticals Inc reports gross margins of 95.0%, compared to 71.5% for the sector. The operating margin is -360.6% (sector: -66.1%). Net profit margin stands at -354.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 1210.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SNDX Debt, Balance Sheet, and Financial Health

Syndax Pharmaceuticals Inc has a debt-to-equity ratio of 720.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 4.40x, indicating strong short-term liquidity. Total debt on the balance sheet is $1M. Cash and equivalents stand at $117M.

SNDX has a beta of 1.03, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Syndax Pharmaceuticals Inc is 40/100, reflecting average volatility within the normal range for its sector.

Syndax Pharmaceuticals Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, Syndax Pharmaceuticals Inc reported revenue of $116M and earnings per share (EPS) of $-3.29. Net income for the quarter was $-302M. Gross margin was 95.0%. Operating income came in at $-300M.

In FY 2025, Syndax Pharmaceuticals Inc reported revenue of $172M and earnings per share (EPS) of $-3.29. Net income for the quarter was $-285M. Revenue grew 627.8% year-over-year compared to FY 2024. Operating income came in at $-273M.

In Q3 2025, Syndax Pharmaceuticals Inc reported revenue of $46M and earnings per share (EPS) of $-0.70. Net income for the quarter was $-61M. Revenue grew 267.0% year-over-year compared to Q3 2024. Operating income came in at $-57M.

In Q2 2025, Syndax Pharmaceuticals Inc reported revenue of $38M and earnings per share (EPS) of $-0.83. Net income for the quarter was $-72M. Revenue grew 984.5% year-over-year compared to Q2 2024. Operating income came in at $-69M.

Over the past 8 quarters, Syndax Pharmaceuticals Inc has demonstrated a growth trajectory, with revenue expanding from $4M to $116M. Investors analyzing SNDX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SNDX Dividend Yield and Income Analysis

Syndax Pharmaceuticals Inc (SNDX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SNDX Momentum and Technical Analysis Profile

Syndax Pharmaceuticals Inc (SNDX) has a momentum factor score of 67/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 1/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

SNDX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Syndax Pharmaceuticals Inc (SNDX) ranks #150 out of 838 stocks based on the Blank Capital composite score. This places SNDX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SNDX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SNDX vs S&P 500 (SPY) comparison to assess how Syndax Pharmaceuticals Inc stacks up against the broader market across all factor dimensions.

SNDX Next Earnings Date

No upcoming earnings date has been announced for Syndax Pharmaceuticals Inc (SNDX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SNDX? — Investment Thesis Summary

Syndax Pharmaceuticals Inc presents a balanced picture with arguments on both sides. The quality score of 16/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. Price momentum is positive at 67/100, suggesting the trend favors buyers.

In summary, Syndax Pharmaceuticals Inc (SNDX) earns a Hold rating with a composite score of 30.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SNDX stock.

Related Resources for SNDX Investors

Explore more research and tools: SNDX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SNDX head-to-head with peers: SNDX vs AZN, SNDX vs SLGL, SNDX vs VMD.